Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 16, 2025Cancer Discovery

Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGF β Axis

View Full Paper
Ask AI
Bookmark
Share

Authors

CECharles H. EarnshawCancer Research UK Manchester InstitutePDPamela DunnArizona State UniversitySCShih‐Chieh ChiangCancer Research UK Manchester Institute

Discussion

Loading...

Member takes

Implication

Observational analysis reveals glucocorticoids improve melanoma outcomes via GARP and TGF β modulation.

Key Points

  • Glucocorticoids trigger tumor control in melanoma by inhibiting GARP expression, enhancing T cell activity.
  • Patients with high GARP expression have decreased survival rates and poor response to immunotherapy.
  • Inhibition of TGF β signaling is crucial for glucocorticoids to effect tumor control in multiple cancer types.
  • High glucocorticoid receptor expression in melanoma correlates with better prognosis and lower TGF β signaling.

Cite This Study

Earnshaw et al. (2025) studied this question.

synapsesocial.com/papers/68f04918e559138a1a06d3bbhttps://doi.org/10.1158/2159-8290.cd-24-1224
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glucocorticoids unleash immune-dependent melanoma control through inhibition of the GARP/TGF-β axis2025
  2. 2Abstract 2557: Glucocorticoids inhibit the GARP/TGF-βaxis initiating immune-dependent melanoma control2026
  3. 3Mind the GARP: How Glucocorticoids Unleash T Cells against Melanoma2026
  4. 4Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer2020 · 146 citations
  5. 5GARP-expressing Tregs as a source of immunosuppressive TGF-β1 in human tumors2025 · 4 citations